ORPHAN
DISEASES
MIK LLC, as part of specialized research programs and non-interventional studies to study the prevalence and choice of etiopathogenetic therapy for some rare (orphan) diseases, provides assistance in solving the problems of diagnosing and treating patients.
CYSTIC FIBROSIS
Research program to collect data on the spectrum of mutations in the CFTR gene to predict the clinical course of the disease and the choice of etiopathogenetic therapy in patients with cystic fibrosis in the Russian Federation.
Drugs not registered in the Russian Federation
TRILEXA®
(Elexacaftor 100mg, Ivacaftor 75mg, Tezacaftor 50mg + Ivacaftor 150mg). The package contains 60 orange film-coated tablets containing the combination elexacaftor/tezacaftor/ivacaftor and 30 blue film-coated tablets containing ivacaftor.
TISURAL®
Levofloxacin, solution for inhalation 240 mg №56
Drugs registered in the Russian Federation
Tobramycin-Gobbi®
Tobramycin, solution for inhalation 60 mg/ml 5 ml №56
ALPHA-1 ANTITRYPSIN DIFINCIENCY
Non-interventional study to study the prevalence of alpha-1 antitrypsin deficiency in patients with emphysema and other chronic bronchopulmonary diseases in the Russian Federation.
Respikam®
Alpha 1-proteinase inhibitor (human), solution for infusion 20 mg/ml 50 ml
PHENYLKETONURIA
Efkuria®
(Sapropterin), dispersible tablets 100 mg №30